EPR plays an important role in food quality control due to its ability to detect and quantify free radicals, also referred to as reactive oxygen species (ROS). Bruker's e-scan beer analyzer can measure the beer oxidation profile to evaluate beer during the many stages of the brewing process. The combination of the e-scan's compact size and Bruker's patented, automated EPR/lagtime assay (US 6,462,546B1) has won considerable acceptance in the brewing industry. SABMiller is one of the largest beer producers in the world and has been a key customer of Bruker for many years. The strong record of close collaboration between Bruker and SABMiller has now set new standards in the field of beer quality and process control.

Professor Barry Axcell, Group Chief Brewer of SABMiller commented: "SABMiller has a long standing commitment to giving our consumers high quality, fresh-tasting beers. We are committed to using only the finest, natural ingredients and rely on the skill of our brewmasters combined with innovative and leading-edge technology such as the e-scan to find natural ways to preserve the fresh taste of our beers."

For further information on e-scan, please visit www.bruker-biospin.com/e-scan.

For information about Bruker BioSpin and Bruker Corporation (NASDAQ: BRKR), visit www.bruker.com.

Based on the proprietary e-scan beer analyzer technology, Bruker is also offering Analytical Services (BAS) for beer shelf life determination and optimization.

CAUTIONARY STATEMENT

Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, risks and uncertainties relating to adverse changes in conditions in the global economy and volatility in the capital markets, the integration of businesses we have acquired or may acquire in the future, changing technologies, product development and market acceptance of our products, the cost and pricing of our products, manufacturing, competition, dependence on collaborative partners and key suppliers, capital spending and government funding policies, changes in governmental regulations, realization of anticipated benefits from economic stimulus programs, intellectual property rights, litigation, and exposure to foreign currency fluctuations and other risk factors discussed from time to time in our filings with the Securities and Exchange Commission. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our recent Proxy Statements on Schedule 14A, our annual report on Form 10-K for the year ended December 31, 2008, our most recent quarterly reports on Form 10-Q and our current reports on Form 8-K. We expressly disclaim any intent or obligation to update these forward-looking statements other than as required by law.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6130239&lang=en

SOURCE: Bruker Corporation

Bruker BioSpin
Dr. Thorsten Thiel, +49 (721) 5161 - 6517
Director of Marketing Communications
thorsten.thiel@bruker.de